Table 1. Type 2 antagonists against bronchial asthma under development.
| Target | Drug Name | Type | Manufacturer | Stage (global) |
|---|---|---|---|---|
| IgE | QGE031 | Antibody | Novartis | P2 |
| IgE | XmAb7195 | Antibody | Xencor | P1 |
| IgE | PF06444752 | Vaccine | Cytos Biotechnology/Pfizer | P1 |
| Membrane IgE | FB825 | Antibody | Fountain Biopharma | P1 |
| IL-13 | Lebrikizumab | Antibody | Roche | P3 |
| IL-13 | Tralokinumab | Antibody | AstraZeneca | P3 |
| IL-13 | QAX576 | Antibody | Novartis | P2 |
| IL-13 | MEDI7836 | Antibody | MedImmune/AstraZeneca | P1 |
| IL-4+13 | QBX258 | Antibody+Compound | Novartis | P2 |
| IL-4R | Dupilumab | Antibody | Regeneron/Sanofi | P3 |
| IL-5 | Mepolizumab | Antibody | GSK | Launched |
| IL-5 | Reslizumab | Antibody | Teva | P3 |
| IL-5R | Benralizumab | Antibody | AstraZeneca/Kyowa Hakko Kirin | P3 |
| Common β | ASM8 | Antisense | Pharmaxis | P2 |
| IL-33 | AMG282 | Antibody | Amgen | P1 |
| TSLP | AMG157/MEDI9929 | Antibody | Amgen/MedImmune/AstraZeneca | P2 |
| CCR3 | AXP1275 | LWMC | Axikin | P2 |
| CCR4 | Mogamulizumab | Antibody | Kyowa Hakko Kirin | P1 |
| CCL11 | Bertilimumab | Antibody | Immune | P1 |
| CRTH2 | OC459/ODC9101 | LWMC | Atopix/Oxagen | P3 |
| CRTH2 | ADC3680 | LWMC | Pulmagen Therapeutics/Teijin | P2 |
| CRTH2 | ARRY502 | LWMC | Array | P2 |
| CRTH2 | QAW039 | LWMC | Novartis | P2 |
| CRTH2 | OC002417/ATX2417 | LWMC | Atopix/Oxagen | P1 |
| CRTH2 | AM461 | LWMC | Panmira | P1 |
| CRTH2 | AM211 | LWMC | Panmira | P1 |
LWMC, low-weight molecular compound.